THU0068 Preclinical Characterization of PRN1008, a Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a RAT Model of Collagen-Induced Arthritis

布鲁顿酪氨酸激酶 体内 医学 关节炎 类风湿性关节炎 药理学 酪氨酸激酶 癌症研究 免疫学 分子生物学 生物 受体 内科学 生物技术
作者
Ronald J. Hill,J. Michael Bradshaw,Angelina Bisconte,Danny Tam,Timothy D. Owens,Ken A. Brameld,Patrick F. Smith,Jens Oliver Funk,David Goldstein,P.A. Nunn
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:74: 216-217 被引量:9
标识
DOI:10.1136/annrheumdis-2015-eular.3641
摘要

Background

Bruton9s Tyrosine Kinase (BTK) is a cytoplasmic signaling molecule downstream from a group of cellular receptors important for disease initiation, propagation, and tissue destruction associated with a variety of autoimmune diseases including rheumatoid arthritis. There is strong pre-clinical validation for BTK as a therapeutic target for autoimmune diseases based on multiple animal models. Principia discovered a potent, selective inhibitor of BTK that targets cysteine through a reversible covalent interaction which results in prolonged residence time and inhibition of the target.

Objectives

To characterize Principia9s novel reversible covalent inhibitor of BTK and demonstrate efficacy in an animal model of rheumatoid arthritis through prolonged target residence time rather than continuous high exposure to the drug.

Methods

Biochemical characterization of PRN1008 was performed utilizing Caliper-based kinase assays, TR-FRET-based off-rate assays, and mass-spectrometry-based reversibility assays. Binding of PRN1008 to BTK was assessed in Ramos B cells, human PBMC and rat splenocytes (for PK/PD studies) using a fluorescent probe-based occupancy assay. Functional effects in B cells were measured by effects of PRN1008 on B cell CD69 expression and proliferation induced by anti-IgM. Cellular selectivity for BTK was demonstrated by lack of potency against a range of off-target cell-based assays. The in vivo efficacy of PRN1008 was tested in a rat model of collagen-induced arthritis.

Results

PRN1008 was found to be very potent against BTK (IC50 =1.3±0.5 nM) and highly selective when tested against a panel of 251 other kinases. Cysteine targeting of BTK by PRN1008 results in a slow off-rate demonstrated by retention of 79±2% of binding to BTK in PBMC 18 hours after washing away the compound in vitro. The covalent cysteine binding was completely reversible after denaturation of the target. Anti-IgM induced human B cell proliferation (10% serum) and B cell CD69 expression (whole blood) were inhibited by PRN1008 with IC50 of 5±2.4 nM and 123±38 nM, respectively. PRN1008 did not block EGFR signaling in epithelial cells or TCR and calcium flux stimulated T cell activation. PRN1008 also did not block IL-4 stimulation of B cells and did not exhibit cytotoxicity in an epithelial cell line HCT-116. In addition, PRN1008 did not block antibody dependent cellular cytotoxicity in combination with anti-CD20 antibodies allowing for potential combination therapies. In vivo PRN1008 demonstrated enduring pharmacodynamic effects after the compound had cleared from circulation, consistent with extended target residence time. PRN1008 also suppressed collagen-induced arthritis in rats in a dose dependent manner which allowed correlation of target occupancy and disease modification.

Conclusions

Our characterization of PRN1008 demonstrated it to be a potent, selective and reversible covalent inhibitor of BTK with extended PD effects in vivo and efficacy in collagen-induced arthritis in rats. These data support continued development of PRN1008 as a therapeutic agent for rheumatoid arthritis.

Disclosure of Interest

R. Hill Shareholder of: Principia Biopharma, Employee of: Principia Biopharma, J. Bradshaw Employee of: Principia Biopharma, A. Bisconte Employee of: Principia Biopharma, D. Tam Employee of: Principia Biopharma, T. Owens Shareholder of: Principia Biopharma, Employee of: Principia Biopharma, K. Brameld Shareholder of: Principia Biopharma, Employee of: Principia Biopharma, P. Smith Consultant for: Principia Biopharma, J. Funk Shareholder of: Principia Biopharma, Employee of: Principia Biopharma, D. Goldstein Shareholder of: Principia Biopharma, Employee of: Principia Biopharma, P. Nunn Employee of: Principia Biopharma
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
liu关闭了liu的文献求助
刚刚
yy发布了新的文献求助10
刚刚
1秒前
1秒前
严xixi完成签到 ,获得积分10
2秒前
2秒前
翟思宇发布了新的文献求助10
2秒前
昏睡的衬衫完成签到,获得积分10
3秒前
黑子完成签到,获得积分10
3秒前
聪明依柔完成签到 ,获得积分10
4秒前
5秒前
candiceli发布了新的文献求助20
5秒前
专注寻菱发布了新的文献求助10
5秒前
宋紫馨完成签到 ,获得积分10
6秒前
ali8ba完成签到,获得积分10
6秒前
三岁放火烧山完成签到,获得积分10
6秒前
dyy123完成签到,获得积分10
7秒前
Fayth完成签到,获得积分0
7秒前
江边拔草完成签到,获得积分10
7秒前
七安发布了新的文献求助10
7秒前
学术智子发布了新的文献求助10
8秒前
李健的小迷弟的应助被Sweetx采纳,获得10
9秒前
9秒前
awang发布了新的文献求助20
10秒前
Tong完成签到,获得积分10
10秒前
10秒前
如意听安完成签到,获得积分10
10秒前
领导范儿的应助被再睡亿分钟采纳,获得10
11秒前
11秒前
12秒前
mmol完成签到,获得积分10
12秒前
huang完成签到,获得积分10
13秒前
xixi发布了新的文献求助10
13秒前
七安完成签到,获得积分20
14秒前
赘婿的应助被dyy123采纳,获得10
14秒前
14秒前
14秒前
yy发布了新的文献求助10
14秒前
大模型的应助被zzh采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651